Trial Profile

SARC038: A Phase 2 Study of Regorafenib in Combination With Nivolumab in Patients With Refractory or Recurrent Osteosarcoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Regorafenib (Primary)
Indications Osteosarcoma
Focus Therapeutic Use

Most Recent Events

18 Apr 2025 Planned primary completion date changed from 1 May 2024 to 1 May 2025.
23 Mar 2023 Status changed from recruiting to active, no longer recruiting.
19 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 May 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com